Tarsus is a privately held, clinical-stage biopharmaceutical company headquartered in Irvine, California. Tarsus was founded in 2017 to bring innovative therapies to a range of diseases in need of better solutions, starting with Demodex blepharitis and eye care.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/08/20 | $60,000,000 | Series B |
Aperture Venture Partners Flying L Partners Frazier Healthcare Partners Horowitz Group Visionary Ventures Fund Vivo Capital  | undisclosed |
